Germline genes hypomethylation and expression define a molecular signature in peripheral blood of ICF patients: Implications for diagnosis and etiology

Guillaume Velasco, Emma L. Walton, Delphine Sterlin, Sabrine Hédouin, Hirohisa Nitta, Yuya Ito, Fanny Fouyssac, André Mégarbané, Hiroyuki Sasaki, Capucine Picard, Claire Francastel

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Background: Immunodeficiency Centromeric Instability and Facial anomalies (ICF) is a rare autosomal recessive disease characterized by reduction in serum immunoglobulins with severe recurrent infections, facial dysmorphism, and more variable symptoms including mental retardation. ICF is directly related to a genomic methylation defect that mainly affects juxtacentromeric heterochromatin regions of certain chromosomes, leading to chromosomal rearrangements that constitute a hallmark of this syndrome upon cytogenetic testing. Mutations in the de novo DNA methyltransferase DNMT3B, the protein ZBTB24 of unknown function, or loci that remain to be identified, lie at its origin. Despite unifying features, common or distinguishing molecular signatures are still missing for this disease. Method. We used the molecular signature that we identified in a mouse model for ICF1 to establish transcriptional biomarkers to facilitate diagnosis and understanding of etiology of the disease. We assayed the expression and methylation status of a set of genes whose expression is normally restricted to germ cells, directly in whole blood samples and epithelial cells of ICF patients. Results: We report that DNA hypomethylation and expression of MAEL and SYCE1 represent robust biomarkers, easily testable directly from uncultured cells to diagnose the most prevalent sub-type of the syndrome. In addition, we identified the first unifying molecular signatures for ICF patients. Of importance, we validated the use of our biomarkers to diagnose a baby born to a family with a sick child. Finally, our analysis revealed unsuspected complex molecular signatures in two ICF patients suggestive of a novel genetic etiology for the disease. Conclusions: Early diagnosis of ICF syndrome is crucial since early immunoglobulin supplementation can improve the course of disease. However, ICF is probably underdiagnosed, especially in patients that present with incomplete phenotype or born to families with no affected relatives. The specific and robust biomarkers identified in this study could be introduced into routine clinical immunology or neurology departments to facilitate testing of patients with suspected ICF syndrome. In addition, as exemplified by two patients with a combination of molecular defects never described before, our data support the search for new types of mutations at the origin of ICF syndrome.

    Original languageEnglish
    Article number56
    JournalOrphanet Journal of Rare Diseases
    Volume9
    Issue number1
    DOIs
    Publication statusPublished - Apr 17 2014

    Fingerprint

    Gene Expression
    Biomarkers
    Methylation
    Immunoglobulins
    Protein Methyltransferases
    Mutation
    Inborn Genetic Diseases
    Heterochromatin
    DNA
    Neurology
    Allergy and Immunology
    Germ Cells
    Cytogenetics
    Intellectual Disability
    Early Diagnosis
    Blood Cells
    Chromosomes
    Epithelial Cells
    Phenotype
    Infection

    All Science Journal Classification (ASJC) codes

    • Genetics(clinical)
    • Pharmacology (medical)

    Cite this

    Germline genes hypomethylation and expression define a molecular signature in peripheral blood of ICF patients : Implications for diagnosis and etiology. / Velasco, Guillaume; Walton, Emma L.; Sterlin, Delphine; Hédouin, Sabrine; Nitta, Hirohisa; Ito, Yuya; Fouyssac, Fanny; Mégarbané, André; Sasaki, Hiroyuki; Picard, Capucine; Francastel, Claire.

    In: Orphanet Journal of Rare Diseases, Vol. 9, No. 1, 56, 17.04.2014.

    Research output: Contribution to journalArticle

    Velasco, Guillaume ; Walton, Emma L. ; Sterlin, Delphine ; Hédouin, Sabrine ; Nitta, Hirohisa ; Ito, Yuya ; Fouyssac, Fanny ; Mégarbané, André ; Sasaki, Hiroyuki ; Picard, Capucine ; Francastel, Claire. / Germline genes hypomethylation and expression define a molecular signature in peripheral blood of ICF patients : Implications for diagnosis and etiology. In: Orphanet Journal of Rare Diseases. 2014 ; Vol. 9, No. 1.
    @article{40d948835eeb4441a814283a304d70b2,
    title = "Germline genes hypomethylation and expression define a molecular signature in peripheral blood of ICF patients: Implications for diagnosis and etiology",
    abstract = "Background: Immunodeficiency Centromeric Instability and Facial anomalies (ICF) is a rare autosomal recessive disease characterized by reduction in serum immunoglobulins with severe recurrent infections, facial dysmorphism, and more variable symptoms including mental retardation. ICF is directly related to a genomic methylation defect that mainly affects juxtacentromeric heterochromatin regions of certain chromosomes, leading to chromosomal rearrangements that constitute a hallmark of this syndrome upon cytogenetic testing. Mutations in the de novo DNA methyltransferase DNMT3B, the protein ZBTB24 of unknown function, or loci that remain to be identified, lie at its origin. Despite unifying features, common or distinguishing molecular signatures are still missing for this disease. Method. We used the molecular signature that we identified in a mouse model for ICF1 to establish transcriptional biomarkers to facilitate diagnosis and understanding of etiology of the disease. We assayed the expression and methylation status of a set of genes whose expression is normally restricted to germ cells, directly in whole blood samples and epithelial cells of ICF patients. Results: We report that DNA hypomethylation and expression of MAEL and SYCE1 represent robust biomarkers, easily testable directly from uncultured cells to diagnose the most prevalent sub-type of the syndrome. In addition, we identified the first unifying molecular signatures for ICF patients. Of importance, we validated the use of our biomarkers to diagnose a baby born to a family with a sick child. Finally, our analysis revealed unsuspected complex molecular signatures in two ICF patients suggestive of a novel genetic etiology for the disease. Conclusions: Early diagnosis of ICF syndrome is crucial since early immunoglobulin supplementation can improve the course of disease. However, ICF is probably underdiagnosed, especially in patients that present with incomplete phenotype or born to families with no affected relatives. The specific and robust biomarkers identified in this study could be introduced into routine clinical immunology or neurology departments to facilitate testing of patients with suspected ICF syndrome. In addition, as exemplified by two patients with a combination of molecular defects never described before, our data support the search for new types of mutations at the origin of ICF syndrome.",
    author = "Guillaume Velasco and Walton, {Emma L.} and Delphine Sterlin and Sabrine H{\'e}douin and Hirohisa Nitta and Yuya Ito and Fanny Fouyssac and Andr{\'e} M{\'e}garban{\'e} and Hiroyuki Sasaki and Capucine Picard and Claire Francastel",
    year = "2014",
    month = "4",
    day = "17",
    doi = "10.1186/1750-1172-9-56",
    language = "English",
    volume = "9",
    journal = "Orphanet Journal of Rare Diseases",
    issn = "1750-1172",
    publisher = "BioMed Central",
    number = "1",

    }

    TY - JOUR

    T1 - Germline genes hypomethylation and expression define a molecular signature in peripheral blood of ICF patients

    T2 - Implications for diagnosis and etiology

    AU - Velasco, Guillaume

    AU - Walton, Emma L.

    AU - Sterlin, Delphine

    AU - Hédouin, Sabrine

    AU - Nitta, Hirohisa

    AU - Ito, Yuya

    AU - Fouyssac, Fanny

    AU - Mégarbané, André

    AU - Sasaki, Hiroyuki

    AU - Picard, Capucine

    AU - Francastel, Claire

    PY - 2014/4/17

    Y1 - 2014/4/17

    N2 - Background: Immunodeficiency Centromeric Instability and Facial anomalies (ICF) is a rare autosomal recessive disease characterized by reduction in serum immunoglobulins with severe recurrent infections, facial dysmorphism, and more variable symptoms including mental retardation. ICF is directly related to a genomic methylation defect that mainly affects juxtacentromeric heterochromatin regions of certain chromosomes, leading to chromosomal rearrangements that constitute a hallmark of this syndrome upon cytogenetic testing. Mutations in the de novo DNA methyltransferase DNMT3B, the protein ZBTB24 of unknown function, or loci that remain to be identified, lie at its origin. Despite unifying features, common or distinguishing molecular signatures are still missing for this disease. Method. We used the molecular signature that we identified in a mouse model for ICF1 to establish transcriptional biomarkers to facilitate diagnosis and understanding of etiology of the disease. We assayed the expression and methylation status of a set of genes whose expression is normally restricted to germ cells, directly in whole blood samples and epithelial cells of ICF patients. Results: We report that DNA hypomethylation and expression of MAEL and SYCE1 represent robust biomarkers, easily testable directly from uncultured cells to diagnose the most prevalent sub-type of the syndrome. In addition, we identified the first unifying molecular signatures for ICF patients. Of importance, we validated the use of our biomarkers to diagnose a baby born to a family with a sick child. Finally, our analysis revealed unsuspected complex molecular signatures in two ICF patients suggestive of a novel genetic etiology for the disease. Conclusions: Early diagnosis of ICF syndrome is crucial since early immunoglobulin supplementation can improve the course of disease. However, ICF is probably underdiagnosed, especially in patients that present with incomplete phenotype or born to families with no affected relatives. The specific and robust biomarkers identified in this study could be introduced into routine clinical immunology or neurology departments to facilitate testing of patients with suspected ICF syndrome. In addition, as exemplified by two patients with a combination of molecular defects never described before, our data support the search for new types of mutations at the origin of ICF syndrome.

    AB - Background: Immunodeficiency Centromeric Instability and Facial anomalies (ICF) is a rare autosomal recessive disease characterized by reduction in serum immunoglobulins with severe recurrent infections, facial dysmorphism, and more variable symptoms including mental retardation. ICF is directly related to a genomic methylation defect that mainly affects juxtacentromeric heterochromatin regions of certain chromosomes, leading to chromosomal rearrangements that constitute a hallmark of this syndrome upon cytogenetic testing. Mutations in the de novo DNA methyltransferase DNMT3B, the protein ZBTB24 of unknown function, or loci that remain to be identified, lie at its origin. Despite unifying features, common or distinguishing molecular signatures are still missing for this disease. Method. We used the molecular signature that we identified in a mouse model for ICF1 to establish transcriptional biomarkers to facilitate diagnosis and understanding of etiology of the disease. We assayed the expression and methylation status of a set of genes whose expression is normally restricted to germ cells, directly in whole blood samples and epithelial cells of ICF patients. Results: We report that DNA hypomethylation and expression of MAEL and SYCE1 represent robust biomarkers, easily testable directly from uncultured cells to diagnose the most prevalent sub-type of the syndrome. In addition, we identified the first unifying molecular signatures for ICF patients. Of importance, we validated the use of our biomarkers to diagnose a baby born to a family with a sick child. Finally, our analysis revealed unsuspected complex molecular signatures in two ICF patients suggestive of a novel genetic etiology for the disease. Conclusions: Early diagnosis of ICF syndrome is crucial since early immunoglobulin supplementation can improve the course of disease. However, ICF is probably underdiagnosed, especially in patients that present with incomplete phenotype or born to families with no affected relatives. The specific and robust biomarkers identified in this study could be introduced into routine clinical immunology or neurology departments to facilitate testing of patients with suspected ICF syndrome. In addition, as exemplified by two patients with a combination of molecular defects never described before, our data support the search for new types of mutations at the origin of ICF syndrome.

    UR - http://www.scopus.com/inward/record.url?scp=84899978054&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84899978054&partnerID=8YFLogxK

    U2 - 10.1186/1750-1172-9-56

    DO - 10.1186/1750-1172-9-56

    M3 - Article

    C2 - 24742017

    AN - SCOPUS:84899978054

    VL - 9

    JO - Orphanet Journal of Rare Diseases

    JF - Orphanet Journal of Rare Diseases

    SN - 1750-1172

    IS - 1

    M1 - 56

    ER -